PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Cancer Cell

Volumn 6, Issue 2, 2004, Pages 117-127

  Nagata, Yoichi ^a   Lan, Keng Hsueh ^a   Zhou, Xiaoyan ^a   Tan, Ming ^a   Esteva, Francisco J ^a   Sahin, Aysegul A ^a   Klos, Kristine S ^a   Li, Ping ^a   Monia, Brett P ^b   Nguyen, Nina T ^a   Hortobagyi, Gabriel N ^a   Hung, Mien Chie ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRASTUZUMAB; TYROSINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; SRC-FAMILY KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 5144226211     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.06.022     Document Type: Article

References (61)

1. Albanell J., Baselga J. Unraveling resistance to trastuzumab (Herceptin). insulin-like growth factor-I receptor, a new suspect J. Natl. Cancer Inst. 93:2001;1830-1832
2. Bange J., Zwick E., Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 7:2001;548-552
3. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12(Suppl 1):2001;S35-S41
4. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene. 20:2001;1465-1475
5. Butler M., McKay R.A., Popoff I.J., Gaarde W.A., Witchell D., Murray S.F., Dean N.M., Bhanot S., Monia B.P. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes. 51:2002;1028-1034
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657
7. Cantley L.C., Neel B.G. New insights into tumor suppression. Pten suppresses tumor formation by restraining the phosphoinostide 3-kinase/Akt pathway Proc. Natl. Acad. Sci. USA. 96:1999;4240-4250
8. Chan P.C., Chen Y.L., Cheng C.H., Yu K.C., Cary L.A., Shu K.H., Ho W.L., Chen H.C. Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation. J. Biol. Chem. 278:2003;44075-44082
9. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760
10. Chui X., Egami H., Yamashita J., Kurizaki T., Ohmachi H., Yamamoto S., Ogawa M. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br. J. Cancer. 73:1996;1233-1236
11. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648
12. Comer F.I., Parent C.A. PI 3-kinases and PTEN. how opposites chemoattract Cell. 109:2002;541-544
13. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14:2001;672-676
14. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 100:2000;387-390
15. Dickman S. Antibodies stage a comeback in cancer treatment. Science. 280:1998;1196-1197
16. Drebin J.A., Link V.C., Stern D.F., Weinberg R.A., Greene M.I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 41:1985;695-706
17. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., Cristofanilli M., Arun B., Esmaeli B., Fritsche H.A., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:2002;1800-1808
18. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., Van De Vijver M.J. Breast cancer response to neoadjuvant chemotherapy. predictive markers and relation with outcome Br. J. Cancer. 88:2003;406-412
19. Frame M.C. Src in cancer. deregulation and consequences for cell behaviour Biochim. Biophys. Acta. 1602:2002;114-130
20. Friedrichs K., Gluba S., Eidtmann H., Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 72:1993;3641-3647
21. Georgescu M.M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. USA. 96:1999;10182-10187
22. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., Buzdar A.U., Frye D.K., Hortobagyi G.N. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83:1991;1797-1805
23. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1989;1165-1172
24. Ignatoski K.M., Maehama T., Markwart S.M., Dixon J.E., Livant D.L., Ethier S.P. ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer. 82:2000;666-674
25. Iijima M., Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 109:2002;599-610
26. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 17:1999;1983-1987
27. Koul D., Jasser S.A., Lu Y., Davies M.A., Shen R., Shi Y., Mills G.B., Yung W.K. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 21:2002;2357-2364
28. Lee S., Yang W., Lan K.H., Sellappan S., Klos K., Hortobagyi G., Hung M.C., Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 62:2002;5703-5710
29. Leslie N.R., Downes C.P. Pten. the down side of pi 3-kinase signalling Cell. Signal. 14:2002;285-295
30. Li D.M., Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA. 95:1998;15406-15411
31. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947
32. Lu Y., Lin Y.Z., LaPushin R., Cuevas B., Fang X., Yu S.X., Davies M.A., Khan H., Furui T., Mao M., et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 18:1999;7034-7045
33. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93:2001;1852-1857
34. Lu Y., Yu Q., Liu J.H., Zhang J., Wang H., Koul D., McMurray J.S., Fang X., Yung W.K., Siminovitch K.A., Mills G.B. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 278:2003;40057-40066
35. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749
36. Muthuswamy S.K., Muller W.J. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene. 11:1995;1801-1810
37. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., Weng L.P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 92:2000;924-930
38. Palka H.L., Green K.J. Roles of plakoglobin end domains in desmosome assembly. J. Cell Sci. 110:1997;2359-2371
39. Parsons R., Simpson L. PTEN and cancer. Methods Mol. Biol. 222:2003;147-166
40. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L., Komminoth P., Lees J.A., Mulligan L.M., Mutter G.L., Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155:1999;1253-1260
41. Petit A.M., Rak J., Hung M.-C., Rockwell P., Goldstein N., Fendly B., Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 151:1997;1523-1530
42. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA. 98:2001;10320-10325
43. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A., Panageas K.S., Arroyo C., Valero V., Currie V., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19:2001;2587-2595
44. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., Kotts C.E., Palladino M.A. Jr., Ullrich A., et al. Monoclonal antibody therapy of human cancer. taking the HER2 protooncogene to the clinic J. Clin. Immunol. 11:1991;117-127
45. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182
46. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792
47. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:1999;60-70
48. Tan M., Grijalva R., Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 59:1999;1620-1625
49. Tan M., Jing T., Lan K.H., Neal C.L., Li P., Lee S., Fang D., Nagata Y., Liu J., Arlinghaus R., et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol. Cell. 9:2002;993-1004
50. Teng D.H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K.L., Vinson V.L., Gumpper K.L., et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57:1997;5221-5225
51. Urano T., Saito T., Tsukui T., Fujita M., Hosoi T., Muramatsu M., Ouchi Y., Inoue S. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 417:2002;871-875
52. Valero V., Holmes F.A., Walters R.S., Theriault R.L., Esparza L., Fraschini G., Fonseca G.A., Bellet R.E., Buzdar A.U., Hortobagyi G.N. Phase II trial of docetaxel. a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J. Clin. Oncol. 13:1995;2886-2894
53. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:2002;719-726
54. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA. 95:1998;5246-5250
55. Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275:2000;21477-21485
56. Xiong S., Grijalva R., Zhang L., Nyuyen N., Pisters P., Pollock R., Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the Heregulin-b1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res. 61:2001;1727-1732
57. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62:2002;4132-4141
58. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19:2000;6115-6121
59. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T.J., Hung M.C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell. 2:1998;581-591. a
60. Yu D., Liu B., Jing T., Sun D., Price J.E., Singletary S.E., Ibrahim N., Hortobagyi G.N., Hung M.C. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 16:1998;2087-2094. b
61. Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y., Hung M.C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275:2000;8027-8031